摘要
目的探讨左旋多巴及恩他卡朋治疗帕金森病的效果。方法入选本组研究的72例帕金森病患者均来自我院,病例资料选取时间为2018年1月至2019年1月,按照随机数字表方法将72例帕金森病患者分成两组。对照组36例患者单独给予左旋多巴治疗,研究组36例患者则给予左旋多巴联合恩他卡朋治疗,检测和对比两组患者治疗前后的白细胞介素6(IL-6)、白细胞介素10(IL-10)、白细胞介素1β(IL-1β)以及肿瘤坏死因子α(TNF-α)等炎性因子水平,评估临床治疗效果,并观察不良反应发生情况。结果研究组、对照组患者的临床治疗有效率分别为97.22%、77.78%,组间数据对比有明显的差异(χ^2=4.571,P<0.05)。治疗后,研究组与对照组的IL-6、IL-10、IL-1β以及TNF-α等炎性因子水平比治疗前均明显降低(P<0.05),并且研究组的上述炎性因子水平均明显低于对照组(P<0.05)。研究组、对照组患者的不良反应发生率分别为5.56%、22.22%,组间数据对比有明显的差异(χ^2=4.180,P=0.040)。结论左旋多巴及恩他卡朋治疗帕金森病疗效显著,可有效降低炎性因子水平,且不良反应发生较少,安全性较高。
Objective To investigate the efficacy of levodopa and entacapone in the treatment of Parkinson's disease.Methods A total of 72 patients with Parkinson's disease enrolled in this study were all from our hospital.Data were selected from January 2018 to January 2019,and 72 patients with Parkinson's disease were divided into two groups according to random number table method.Control group 36 patients were given levodopa treatment alone,study of 36 patients were given levodopa joint entacapone treatment,detection,and compared two groups of patients before and after treatment of interleukin 6(IL-6),interleukin 10(IL-10),interleukins 1 beta(IL-1 beta)and tumor necrosis factor alpha(TNF alpha)level of inflammatory factors such.To evaluate the clinical treatment effect and observe the occurrence of adverse reactions.Results The effective rate of study group and control group were 97.22%and 77.78%,respectively,there was significant difference between groups(χ^2=4.571,P<0.05).After treatment,the levels of inflammatory factors such as IL-6,IL-10,IL-1βand TNF-αin the study group and control group were significantly lower than those before treatment(P<0.05),and the levels of these inflammatory factors in the study group were significantly lower than those in the control group(P<0.05).The incidence of adverse reactions in the study group and the control group was 5.56%and 22.22%,respectively,there was significant difference between groups(χ^2=4.180,P=0.040).Conclusion Levodopa and entacapone have significant efficacy in the treatment of Parkinson's disease,which can effectively reduce the level of inflammatory factors,and the occurrence of adverse reactions is less,and the safety is high.
作者
杨子微
YANG Ziwei(Department of Neurology,Jinzhou Central Hospital,Jinzhou 121000,China)
出处
《中国医药指南》
2020年第36期51-52,共2页
Guide of China Medicine
关键词
帕金森病
左旋多巴
恩他卡朋
治疗效果
不良反应
Parkinson's disease
Levodopa
Entacapone
Therapeutic effect
Adverse reactions
